Oric Pharmaceuticals Inc

ORIC remains in a Stage 2 corrective reset within a long-term uptrend, with a Bullish Pivot Point pattern signaling structural repair. The stock holds above rising 9- and 21-period EMAs, offering a favorable entry on pullbacks. Overhead resistance at the flat 50-day MA presents a key risk, but current momentum, neutral overbought/oversold context, and shallow pullback dynamics support immediate participation.

• ↑$280.4 M cash funds operations into 2H 2024
• ↑Three INDs filed (ORIC 533, 114, 944); data due H1 2023
• ↓Q4 2021 net loss $22.8 M; 2021 expenses of $78.9 M highlight burn rate